With $69M Deal, AbbVie Turns to Voyager for an Alzheimer's Gene Therapy

With $69M Deal, AbbVie Turns to Voyager for an Alzheimer's Gene Therapy  Xconomy AbbVie steers past the wreckage, reserves $224M to kick off a new approach with Voyager to fight Alzheimer's  Endpoints News Voyager Therapeutics inks deal with AbbVie to develop anti-tau antibodies in neurodegenerative diseases  Seeking AlphaFull coverage

Read More ...
With $69M Deal, AbbVie Turns to Voyager for an Alzheimer's Gene Therapy published February 20, 2018 at 08:34PM. Original Source Link : https://www.xconomy.com/boston/2018/02/20/with-69m-deal-abbvie-turns-to-voyager-for-an-alzheimers-gene-therapy/

loading...